Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -9.92%-50.74M | ---- | -158.38%-46.16M | ---- | -4.40%79.07M | ---- | 14.99%82.71M | ---- | 99.03%71.93M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | -124.54%-4.36M | ---- | -398.71%-1.94M | ---- | -582.46%-389K | ---- | -32.56%-57K | ---- | 28.33%-43K |
| Impairment and provisions: | ---- | 156.12%1.55M | ---- | -112.08%-2.76M | ---- | 231.63%22.81M | ---- | 648.53%6.88M | ---- | -42.38%919K |
| -Impairmen of inventory (reversal) | ---- | 79.00%-1.5M | ---- | -170.06%-7.16M | ---- | 395.92%10.22M | ---- | 188.98%2.06M | ---- | -272.79%-2.32M |
| -Other impairments and provisions | ---- | -30.74%3.05M | ---- | -65.06%4.4M | ---- | 161.40%12.6M | ---- | 49.01%4.82M | ---- | 45.94%3.23M |
| Revaluation surplus: | ---- | 158.53%535K | ---- | ---914K | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other fair value changes | ---- | 158.53%535K | ---- | ---914K | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset sale loss (gain): | ---- | -561.54%-86K | ---- | 99.98%-13K | ---- | ---83.19M | ---- | ---- | ---- | ---- |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -561.54%-86K | ---- | ---13K | ---- | ---- | ---- | ---- | ---- | ---- |
| -Loss (gain) from selling other assets | ---- | ---- | ---- | ---- | ---- | ---83.19M | ---- | ---- | ---- | ---- |
| Depreciation and amortization: | ---- | 10.57%15.54M | ---- | 24.23%14.06M | ---- | 3.61%11.32M | ---- | 8.47%10.92M | ---- | 17.00%10.07M |
| -Depreciation | ---- | 10.57%15.54M | ---- | 24.23%14.06M | ---- | 3.61%11.32M | ---- | 8.47%10.92M | ---- | 17.00%10.07M |
| Financial expense | ---- | -35.52%2.86M | ---- | 275.38%4.44M | ---- | -34.08%1.18M | ---- | -16.57%1.79M | ---- | 25.97%2.15M |
| Special items | ---- | 1.84%5.58M | ---- | 12,002.17%5.48M | ---- | -130.00%-46K | ---- | -107.63%-20K | ---- | 551.72%262K |
| Operating profit before the change of operating capital | ---- | -4.70%-29.12M | ---- | -190.45%-27.81M | ---- | -69.92%30.75M | ---- | 19.86%102.22M | ---- | 77.94%85.28M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | -74.20%6.02M | ---- | 1,437.25%23.34M | ---- | 92.76%-1.75M | ---- | -734.56%-24.09M | ---- | 806.89%3.8M |
| Accounts receivable (increase)decrease | ---- | 988.05%8.84M | ---- | 106.25%812K | ---- | 20.31%-13M | ---- | 18.68%-16.32M | ---- | -17.48%-20.06M |
| Accounts payable increase (decrease) | ---- | 173.71%4.33M | ---- | -39.36%-5.87M | ---- | -151.71%-4.22M | ---- | 218.52%8.15M | ---- | -36.69%-6.88M |
| prepayments (increase)decrease | ---- | 57.43%5.26M | ---- | 188.11%3.34M | ---- | 67.93%-3.79M | ---- | -1,102.71%-11.83M | ---- | 21.40%1.18M |
| Special items for working capital changes | ---- | -104.13%-431K | ---- | 256.82%10.44M | ---- | 50.10%-6.66M | ---- | -589.69%-13.34M | ---- | -40.81%2.73M |
| Cash from business operations | -33.25%-1.62M | -220.32%-5.11M | -114.10%-1.21M | 217.35%4.24M | 148.38%8.6M | -97.02%1.34M | -166.32%-17.77M | -32.17%44.8M | 70.43%26.8M | 114.02%66.05M |
| Other taxs | -402.29%-2.64M | 107.22%739K | 108.90%872K | 23.49%-10.24M | 11.31%-9.8M | 24.08%-13.39M | 7.05%-11.05M | -29.48%-17.63M | -95.88%-11.89M | -35.76%-13.62M |
| Net cash from operations | -1,150.29%-4.25M | 27.21%-4.37M | 71.69%-340K | 50.22%-6M | 95.83%-1.2M | -144.35%-12.05M | -293.28%-28.82M | -48.18%27.17M | 54.43%14.91M | 151.71%52.43M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -16.70%1.36M | 2,256.91%4.27M | 1,203.20%1.63M | -53.47%181K | -53.53%125K | 582.46%389K | 2,590.00%269K | 32.56%57K | -47.37%10K | -28.33%43K |
| Loan receivable (increase) decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 71.94%-4.36M | 63.53%-4.36M | 24.18%-15.53M |
| Decrease in deposits (increase) | --40M | ---- | ---- | ---- | ---- | ---- | --2.75M | ---2.71M | ---- | ---- |
| Sale of fixed assets | ---- | 592.31%90K | 592.31%90K | --13K | --13K | ---- | ---- | ---- | ---- | --20K |
| Purchase of fixed assets | -82.89%-7.99M | 44.18%-6.23M | -31.62%-4.37M | -196.15%-11.16M | -77.72%-3.32M | 32.24%-3.77M | -122.26%-1.87M | -316.63%-5.56M | -94.00%-840K | 57.59%-1.34M |
| Purchase of intangible assets | ---- | 18.03%-2.26M | -1,710.87%-833K | 61.16%-2.76M | 79.56%-46K | -98.85%-7.11M | -33.93%-225K | -332.93%-3.58M | ---168K | 49.57%-826K |
| Cash on investment | ---- | ---- | ---- | ---8.89M | ---4.34M | ---- | ---- | ---- | ---- | ---- |
| Net cash from investment operations | 1,058.63%33.37M | 81.70%-4.14M | 53.98%-3.48M | -115.58%-22.62M | -915.09%-7.56M | 35.04%-10.49M | 117.33%928K | 8.38%-16.15M | 56.61%-5.36M | 30.07%-17.63M |
| Net cash before financing | 862.08%29.12M | 70.28%-8.51M | 56.41%-3.82M | -26.95%-28.61M | 68.57%-8.77M | -304.58%-22.54M | -391.89%-27.89M | -68.34%11.02M | 455.60%9.56M | 895.11%34.8M |
| Cash flow from financing activities | ||||||||||
| New borrowing | --9.84M | -88.08%5.49M | ---- | --46M | --46M | ---- | ---- | -58.85%15.78M | -57.43%15.78M | 45.01%38.35M |
| Refund | -101.53%-3.03M | -25.54%-3.05M | -56.50%-1.5M | 93.25%-2.43M | 97.52%-961K | -58.37%-35.95M | -103.51%-38.73M | 13.04%-22.7M | 5.84%-19.03M | -35.49%-26.1M |
| Issuing shares | ---- | ---- | ---- | ---- | ---- | 382.97%246M | --246M | --50.94M | ---- | ---- |
| Interest paid - financing | 23.25%-1.07M | -18.93%-2.75M | -62.27%-1.39M | -95.26%-2.31M | -13.53%-856K | 34.08%-1.18M | 6.10%-754K | 16.57%-1.79M | 31.25%-803K | -25.97%-2.15M |
| Dividends paid - financing | ---- | 75.23%-4.74M | 75.23%-4.74M | 60.12%-19.14M | 60.12%-19.14M | -39.23%-48M | -74.86%-48M | -701.74%-34.48M | ---27.45M | 10.42%-4.3M |
| Absorb investment income | -81.88%336K | 83.86%3.82M | 3,042.37%1.85M | --2.08M | --59K | ---- | ---- | ---- | ---- | ---- |
| Issuance expenses and redemption of securities expenses | ---- | 75.73%-10.17M | 94.65%-1.98M | 30.38%-41.89M | -113.26%-37.03M | -3,445.96%-60.18M | -2,146.57%-17.37M | -1,257.60%-1.7M | ---773K | ---125K |
| Other items of the financing business | ---- | ---- | ---- | ---37.48M | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from financing operations | 119.27%2.35M | 68.35%-19.67M | 21.78%-12.18M | -166.21%-62.13M | -111.34%-15.57M | 21,774.13%93.84M | 488.19%137.29M | 141.49%429K | -391.01%-35.37M | 80.33%-1.03M |
| Effect of rate | 351.72%292K | -171.25%-565K | 90.42%-116K | 128.03%793K | 34.04%-1.21M | -406.50%-2.83M | -817.19%-1.84M | -28.89%923K | 12,700.00%256K | 128.92%1.3M |
| Net Cash | 296.64%31.47M | 68.95%-28.17M | 34.25%-16M | -227.27%-90.75M | -122.25%-24.34M | 522.93%71.3M | 523.84%109.4M | -66.10%11.45M | -372.68%-25.81M | 450.47%33.77M |
| Begining period cash | -55.56%22.99M | -63.49%51.72M | -63.49%51.72M | 93.53%141.68M | 86.45%141.68M | 20.33%73.21M | 24.90%75.99M | 136.07%60.84M | 136.07%60.84M | -26.03%25.77M |
| Cash at the end | 53.75%54.74M | -55.56%22.99M | -69.34%35.61M | -63.49%51.72M | -36.73%116.13M | 93.53%141.68M | 420.27%183.55M | 20.33%73.21M | 0.12%35.28M | 136.07%60.84M |
| Cash balance analysis | ||||||||||
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.